SCHEMBL1996221

SCHEMBL1996221

COC(=O)CN(Cc1ccc(Br)cc1)C(N)=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
HPGD P15428 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GLA P06280 1/20 0.39
CYP1A2 P05177 1/20 0.38
ATM Q13315 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
EPHX1 P07099 1/20 0.38
TP53 P04637 2/20 0.38
IDO1 P14902 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16590355 0.80 KMT2A (0.53) MEN1KMT2AHPGDTDP1L3MBTL1
SCHEMBL10958880 0.73 NR1D1 (0.51) KMT2AHPGDKDM4EALDH1A1LMNA
SCHEMBL28791227 0.72 HPGD (0.46) MEN1KMT2AHPGDCYP11B1CYP11B2
SCHEMBL28791233 0.71 HPGD (0.45) MEN1KMT2AHPGDCYP11B1CYP11B2
SCHEMBL502785 0.71 CYP4F2 (0.63) MEN1KMT2AHPGDL3MBTL1KDM4E
SCHEMBL3431592 0.71 HPGD (0.42) MEN1KMT2AHPGDCYP11B1CYP11B2
SCHEMBL13244937 0.71 PTPN1 (0.37) KMT2AALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL25426321 0.70 ALDH1A1 (0.58) MEN1KMT2ATDP1L3MBTL1ALDH1A1
SCHEMBL9372536 0.70 ALOX5 (0.53) MEN1KMT2AHPGDKDM4EALDH1A1
SCHEMBL1858237 0.69 IDO1 (0.55) MEN1KMT2AHPGDCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 MEN1 3145/4885KMT2A 1431/4885HPGD 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.